EU Top Court Rules in Favor of Illumina in $7.1 Billion Grail Deal Probe

Sep 3, 2024, 07:52 AM

The European Union's top court has ruled in favor of Illumina, a U.S. gene sequencing company, in its legal battle against EU antitrust regulators. The court determined that the EU overstepped its authority by investigating Illumina's $7.1 billion bid for Grail, a cancer diagnostic test maker. This ruling marks a significant victory for Illumina, which had previously abandoned the $7 billion bid due to regulatory scrutiny.